Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.

Detalles Bibliográficos
Autores principales: Hatırnaz Ng, Özden, Eşkazan, Ahmet Emre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924416/
https://www.ncbi.nlm.nih.gov/pubmed/35294914
http://dx.doi.org/10.1016/j.tranon.2022.101394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924416/
https://www.ncbi.nlm.nih.gov/pubmed/35294914
http://dx.doi.org/10.1016/j.tranon.2022.101394

Ejemplares similares